Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565260 | 1.00 | HSD17B10 (0.42) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 | |
| SCHEMBL30012690 | 1.00 | HSD17B10 (0.42) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL29888500 | 0.98 | HSD17B10 (0.41) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 | |
| Iodide SCHEMBL30094907 | 0.98 | HSD17B10 (0.41) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL6888158 | 0.98 | HSD17B10 (0.41) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 | |
| Bromide SCHEMBL31362248 | 0.98 | HSD17B10 (0.41) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 | |
| Water SCHEMBL10356867 | 0.96 | HSD17B10 (0.39) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 | |
| SCHEMBL4490877 | 0.87 | ALDH1A1 (0.38) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 | |
| SCHEMBL4507833 | 0.83 | ALDH1A1 (0.38) | HSD17B10ALDH1A1TDP1HIF1ACYP1B1 | |
| SCHEMBL30785821 | 0.81 | HSD17B10 (0.39) | HSD17B10CYP2A6ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158639-A1 | PROCESS FOR PREPARING INDOCYANINE GREEN | ICROM SRL (IT) | 2024-05-16 | — | — | US | claimed |
| WO-2023037843-A1 | NOVEL DOUBLE-SQUARAINE DYE AND METHOD FOR PRODUCING SAME | 国立大学法人九州工業大学 | 2023-03-16 | — | — | WO | claimed |
| US-10976319-B2 | Cell response assay for cancer and methods of producing and using same | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2021-04-13 | — | — | US | claimed |
| EP-3664892-A2 | TUNABLE LUMINESCENT ORGANIC SALTS FOR ENHANCED IMAGING AND PHOTODYNAMIC THERAPY | Board of Trustees of Michigan State University (US) | 2020-06-17 | — | — | EP | claimed |
| US-20190339278-A1 | CELL RESPONSE ASSAY FOR CANCER AND METHODS OF PRODUCING AND USING SAME | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2019-11-07 | — | — | US | claimed |
| EP-2748337-B1 | CELL RESPONSE ASSAY FOR CANCER AND METHODS OF PRODUCING AND USING SAME | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2019032683-A2 | TUNABLE LUMINESCENT ORGANIC SALTS FOR ENHANCED IMAGING AND PHOTODYNAMIC THERAPY | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2019-02-14 | — | — | WO | claimed |
| EP-3289615-A1 | ORGANIC SALTS FOR HIGH VOLTAGE ORGANIC AND TRANSPARENT SOLAR CELLS | Board of Trustees of Michigan State University (US) | 2018-03-07 | — | — | EP | claimed |
| US-20170153241-A1 | CELL RESPONSE ASSAY FOR CANCER AND METHODS OF PRODUCING AND USING SAME | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-06-01 | — | — | US | claimed |
| WO-2016176008-A1 | ORGANIC SALTS FOR HIGH VOLTAGE ORGANIC AND TRANSPARENT SOLAR CELLS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2016-11-03 | — | — | WO | claimed |
| EP-1506456-A4 | RADIATION FILTER ELEMENT AND MANUFACTURING PROCESSES THEREFORE | DU PONT (US) | 2006-06-14 | — | — | EP | claimed |
| EP-1636860-A2 | METHODS FOR FORMING PATTERNS OF A FILLED DIELECTRIC MATERIAL ON SUBSTRATES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1506456-A1 | RADIATION FILTER ELEMENT AND MANUFACTURING PROCESSES THEREFORE | E.I. du Pont de Nemours and Company (US) | 2005-02-16 | — | — | EP | claimed |
| WO-2005004205-A2 | METHODS FOR FORMING PATTERNS OF A FILLED DIELECTRIC MATERIAL ON SUBSTRATES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-01-13 | — | — | WO | claimed |
| US-6730691-B1 | OPHTHALMIC SOLUTION FOR INHIBITING VISUAL ANOMALIES EXPERIENCED BY AN INDIVIDUAL WHO UNDERGONE REFRACTIVE EYE SURGERY COMPRISING ALPHA ADRENERGIC BLOCKING AGENTS, ONE OR MORE ANTI-IRRITANT AGENTS, AND ONE OR MORE ANTI-INFLAMMATORY | GALIN MILES A (US) | 2004-05-04 | — | — | US | claimed |
| JP-2003535817-A | — | — | 2003-12-02 | — | — | JP | claimed |
| WO-2003098351-A1 | RADIATION FILTER ELEMENT AND MANUFACTURING PROCESSES THEREFORE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-11-27 | — | — | WO | claimed |
| EP-1047406-B1 | AUTOCLAVABLE PHARMACEUTICAL COMPOSITIONS CONTAINING A CHELATING AGENT | NOVARTIS AG (CH) | 2003-04-23 | — | — | EP | claimed |
| EP-1255540-A1 | OPHTHALMIC USE OF ALPHA ADRENERGIC BLOCKING AGENTS | Galin, Miles A. (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001058438-A1 | OPHTHALMIC USE OF ALPHA ADRENERGIC BLOCKING AGENTS | GALIN MILES A (US) | 2001-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158639-A1 | PROCESS FOR PREPARING INDOCYANINE GREEN | INTS9, CA9, SCN9A | HSD17B10 1491/4885CYP2A6 2412/4885ALDH1A1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.